Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galium-Heel is a multicomponent, multitarget homeopathic medicinal product developed by Heel and researched by Guna. It is composed of a complex mixture of botanical and mineral ingredients in low-dose dilutions, including *Galium aparine*, *Galium mollugo*, *Sedum acre*, and *Thuja occidentalis*. In preclinical in vitro studies, Galium-Heel has been shown to modulate the activity of dermal fibroblasts, specifically influencing their growth, morphology, and the production and remodeling of the extracellular matrix (ECM). This research suggests potential applications in skin health and tissue regeneration by affecting the structural integrity and biological activity of the dermal layer. Traditionally, it is used to stimulate non-specific defense mechanisms, particularly in the context of chronic diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Galium-Heel.